Welcome to Markets Desk, here's what's moving the needle right now.
Wall Street's anxiety about a market crash has been running hot, but seventy-five years of market history suggests investors are watching the wrong signals. While inflation, interest rates, and labor data dominate the conversation, historical patterns point to different leading indicators that have more reliably predicted serious downturns — a reminder that fear itself can distort where you point your attention.
Shifting to healthcare, the weight-loss drug race remains one of the most consequential equity stories heading into two thousand twenty-six. Eli Lilly and Novo Nordisk are both commanding serious investor interest, but Lilly's aggressive expansion in metabolic health treatments and its accelerating revenue trajectory give it a compelling edge, even as Novo defends its formidable global market position.
And in cannabis, Tilray Brands is trading below four dollars, raising the obvious question of whether the discount represents value or a warning. The short answer from analysts is closer to warning — the company's pivot into beverages hasn't produced the growth story needed to justify fresh capital, and without a clear federal catalyst in the United States, the upside remains difficult to underwrite.
That's the tape. Markets Desk, signing off the floor.
